CHNQD-01281

CHNQD-01281, a derivative of Brefeldin A (HY-16592), is a EGFR modulator. CHNQD-01281 has strong antiproliferative activities against cancer cells (IC50: 0.079 and 0.081 μM for T24 and J82 cells, respectively) . CHNQD-01281 regulates both EGFR/PI3K/AKT and EGFR/ERK pathways and mediates the chemotactic effect of chemokines on immune effector cells. CHNQD-01281 remarkably inhibits tumor growth in T24 xenograft mice model and prolongs the survival time in MB49 allogeneic mice model via inducing infiltration of cytotoxic T cells[1].

Product Specifications

CAS Number

[2762488-97-9]

UNSPSC

12352005

Target

Drug Derivative; EGFR

Related Pathways

JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

O[C@@H]1C[C@]2([H])[C@@](/C=C/CCC[C@H](C)OC(/C=C/[C@H]2OC(/C=C/C3=CN=CC=C3)=O)=O)([H])C1

Molecular Formula

C24H29NO5

Molecular Weight

411.49

References & Citations

[1]Liu JY, et al. Discovery of a potential bladder cancer inhibitor CHNQD-01281 by regulating EGFR and promoting infiltration of cytotoxic T cells. Mar Life Sci Technol. 2024 Aug 5;6 (3) :502-514.